Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: USP37, a versatile deubiquitinase, plays a pivotal role in numerous cellular functions. Although its involvement in cancer development is well-established, the comprehensive pan-cancer analysis of USP37 remains relatively uncharted.

Methods: RNA sequencing data from both normal and cancerous tissues were retrieved from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases. Genomic alterations in USP37 across multiple cancer types were examined using cBioPortal. Protein-related information on USP37 was sourced from the Human Protein Atlas (HPA) and Protein-Protein Interaction (PPI) databases. Additionally, Western blotting was conducted to evaluate USP37 expression in clinical samples and pancreatic cancer cell lines. The prognostic relevance of USP37 across various cancers was analyzed using univariate Cox regression and Kaplan-Meier survival curves. Gene Set Enrichment Analysis (GSEA) was performed to identify cancer hallmarks associated with USP37. USP37 protein levels were quantified via immunoblotting, and and functional assays were employed to assess its role in the proliferation of pancreatic cancer cells.

Results: USP37 was found to be aberrantly expressed in several tumor types, with significant association with poor prognosis in certain cancers, including pancreatic cancer. Its expression was also strongly correlated with immune regulators, tumor mutational burden (TMB), and microsatellite instability (MSI), highlighting its potential as a predictive marker for immunotherapy outcomes. Functional assays demonstrated that USP37 fosters proliferation, migration, and invasion in pancreatic cancer cells, further underscoring its role as an oncogene.

Conclusion: USP37 holds promise as a biomarker and therapeutic target in clinical oncology, providing new insights into its function in cancer.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12415066PMC
http://dx.doi.org/10.3389/fcell.2025.1659747DOI Listing

Publication Analysis

Top Keywords

pancreatic cancer
20
usp37
12
cancer
10
pan-cancer analysis
8
analysis usp37
8
functional assays
8
pancreatic
5
integrative pan-cancer
4
usp37 functional
4
functional validation
4

Similar Publications

Mitochondrial ClpX Inhibition Induces Ferroptosis and Blocks Pancreatic Cancer Cell Proliferation.

Chembiochem

September 2025

School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, 310024, P. R. China.

The ATPase caseinolytic protease X (ClpX), forming the ClpXP complex with caseinolytic protease P (ClpP), is essential for mitochondrial protein homeostasis. While ClpP targeting is a recognized anticancer strategy, the role of ClpX in cancer remains underexplored. In pancreatic ductal adenocarcinoma (PDAC), elevated CLPX expression correlates with poor prognosis, suggesting its oncogenic function.

View Article and Find Full Text PDF

Is every pancreatic cancer patient a palliative care patient?

Ann Palliat Med

September 2025

Brown University Health Cancer Institute, Providence, RI, USA; Division of Geriatrics and Palliative Medicine, Department of Medicine, Alpert Medical School of Brown University, Providence, RI, US.

ancreatic cancer is an aggressive disease and often presents at an advanced stage with no curative options. The disease is often characterized by rapid progression, limited or short-lived responsiveness to standard therapies, and a profound impact on patients' quality of life. Despite advances in targeted therapies and immunotherapy, curative outcomes remain elusive for the majority of patients with advanced or high-grade disease with a 5-year survival rate of less than 10%.

View Article and Find Full Text PDF

This study investigates the unique syneresis (self-shrinking) behavior of N-Terminally Fmoc-protected amino acid, Fmoc-hPhe-OH (Fmoc-homo-L-phenylalanine, abbreviated in this work as hF)-based hydrogel, and its potential in environmental remediation applications. Fmoc-hPhe-OH (hF) forms a hydrogel in 50 mM phosphate buffer (PB) of pH 7.4.

View Article and Find Full Text PDF

Elesclomol-Copper combination synergistically targets mitochondrial metabolism in cancer stem cells to overcome chemoresistance in pancreatic ductal adenocarcinoma.

Mol Ther

September 2025

Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China; State Key Laboratory of Systems Medicine for Cancer, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Pancreatic Cancer Heterogeneity, Candiolo Cancer Institute

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor prognosis, partly due to cancer stem cells (CSCs) that drive progression and treatment resistance. We explored the therapeutic potential of inducing cuproptosis, a copper-dependent regulated cell death, in CSC-enriched PDAC models. Using human and murine PDAC models, we evaluated elesclomol, a copper transport enhancer.

View Article and Find Full Text PDF

Flexible suction-coagulation probe restores dexterity in robot-assisted surgery: bench-to-bedside evaluation.

Surg Endosc

September 2025

Department of Next Generation Endoscopic Intervention (Project ENGINE), Graduate School of Medicine, The University of Osaka, Suite 0802, BioSystems Bldg., 1-3, Yamadaoka, Suita, Osaka, 565-0871, Japan.

Objective: Rigid suction-coagulation probes constrain the wrist-like articulation that is central to robotic surgery. We therefore designed a 5-mm single-use flexible suction ball coagulator (flex-SBC) with a modified core design to restore dexterity and assessed its mechanical performance and early clinical feasibility, including the effect of the common robotic gripping strategies on suction flow.

Methods: Preclinical.

View Article and Find Full Text PDF